Sorafenib Therapy for Hepatocellular Carcinoma in an HIV–HCV Coinfected Patient: A Case Report
| العنوان: | Sorafenib Therapy for Hepatocellular Carcinoma in an HIV–HCV Coinfected Patient: A Case Report |
|---|---|
| المؤلفون: | Paolo Costa, Alfredo Scalzini, Enrico Aitini, Alberto Tagliani, Rita Cengarle, Giovanni Carlo Fibbia, Giorgio Perboni, Barbara Morandini |
| المصدر: | The Oncologist. 15:142-145 |
| بيانات النشر: | Oxford University Press (OUP), 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Adult, Male, Niacinamide, Sorafenib, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, Exacerbation, Pyridines, Hepatitis C virus, Population, Antineoplastic Agents, HIV Infections, Comorbidity, medicine.disease_cause, Gastroenterology, Risk Factors, Internal medicine, medicine, Carcinoma, Humans, education, education.field_of_study, business.industry, Phenylurea Compounds, Benzenesulfonates, Liver Neoplasms, HIV Protease Inhibitors, Hepatitis C, medicine.disease, digestive system diseases, Oncology, Hepatocellular carcinoma, Immunology, Coinfection, The Community Oncologist: Case Report, business, medicine.drug |
| الوصف: | Background/Aims. HIV and hepatitis C virus (HCV) share common modes of transmission, resulting in about 33% incidence of coinfection among people infected with HIV. The survival benefit from highly effective antiretroviral therapy (HAART) for HIV infection is resulting in an increased incidence of hepatocellular carcinoma (HCC) in this population. There are no reports to date regarding the coadministration of HAART and sorafenib for hepatocellular carcinoma. Methods. We report the case of a 42-year-old male patient coinfected with HIV and HCV who developed advanced HCC not amenable to curative therapy. The patient was treated with sorafenib, an oral multikinase inhibitor shown to lead to a longer median survival time and time to progression in patients with advanced HCC. Antiretroviral therapy was continued during sorafenib therapy. Results. The patient achieved a partial tumor response after 3 months and continued to respond at subsequent assessments. His serum α-fetoprotein normalized from 2,172 IU/ml to 2 IU/ml. He had durable stable disease after 23 months of therapy. Antiretroviral therapy was efficacious (CD4+ lymphocyte count, 377/μl; HIV viremia, Conclusions. This is the first report in which sorafenib has been successfully used to treat HCC in a patient with HIV–HCV coinfection. |
| تدمد: | 1549-490X 1083-7159 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ee61eca197a6774e597c8fb2bc66cf https://doi.org/10.1634/theoncologist.2010-0010 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....23ee61eca197a6774e597c8fb2bc66cf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1549490X 10837159 |
|---|